Product Description
ARKD-104 is a small molecule that boosts progranulin levels as well as the activity of its cleavage products, the granulin peptides. (Sourced from: https://www.alzforum.org/news/conference-coverage/pumping-progranulin-scientists-show-new-efforts-get-it-done)
Mechanisms of Action: Progranulin Enhancer
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Arkuda Therapeutics
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Dementia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|